CARsgen Secures European Patent for GPC3 CAR-T Therapy
CARsgen Therapeutics Holdings Limited has achieved a significant victory concerning its European patent for a GPC3-targeted CAR-T cell therapy. On July 3, 2025, a U.S.-based biotechnology firm withdrew its appeal…